E&G Advisors’s AstraZeneca AZN Stock Holding History

E&G Advisors’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$292K	Buy	1,541 +50	+3%	+$9.4K	0.06%	197
2026 Q1	$294K	Buy	1,491 +50	+3%	+$9.64K	0.07%	181
2025 Q4	$265K	Hold	1,441	–	–	0.06%	188
2025 Q3	$221K	Buy	+1,441	New	+$218K	0.05%	207
2025 Q2	–	Sell	-1,480	Closed	-$218K	–	211
2025 Q1	$218K	Buy	+1,480	New	+$214K	0.06%	192
2024 Q4	–	Sell	-1,505	Closed	-$235K	–	217
2024 Q3	$235K	Hold	1,505	–	–	0.06%	192
2024 Q2	$235K	Sell	1,505 -209	-12%	-$31.4K	0.07%	189
2024 Q1	$232K	Buy	+1,714	New	+$227K	0.07%	183

Other funds holding AZN

Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return

CDDEC

Caisse Des Depots Et Consignations Paris, France $5.91B AUM 35.65% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

AAMU

AEGON Asset Management (UK) Edinburgh, United Kingdom $9.38B AUM 48.94% 1-Year Est. Return

Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

AIM

Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return

ASR Vermogensbeheer Utrecht, Netherlands $9.71B AUM 37.32% 1-Year Est. Return

MIF

Mediolanum International Funds Dublin 1, Ireland $11.7B AUM 47.18% 1-Year Est. Return

ZIC

ZWJ Investment Counsel Atlanta, Georgia $3.09B AUM 39.43% 1-Year Est. Return

E&G Advisors's AZN Position: Q2 2026 in Review

E&G Advisors increased its AstraZeneca (AZN) stake by 3.4% in Q2 2026, buying an estimated $9.4K and bringing the position to 1,541 shares worth $292K. The position accounts for 0.06% of the portfolio, ranked #197.

E&G Advisors first reported a position in AZN in Q1 2024 and has held it in 8 quarters since. The position peaked at $294K in Q1 2026. 443 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

E&G Advisors held 1,541 shares of AstraZeneca worth $292K as of Q2 2026.
E&G Advisors bought 50 AstraZeneca shares in Q2 2026, an estimated $9.4K.
AstraZeneca made up 0.06% of E&G Advisors's portfolio in Q2 2026, its #197 holding.
E&G Advisors first reported a position in AstraZeneca in Q1 2024 and has held it in 8 quarters since.
E&G Advisors's AstraZeneca position peaked at $294K in Q1 2026.
443 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on E&G Advisors's 13F filing for Q2 2026, filed 23 Jul 2026.